Capricor Therapeutics Inc（CAPR）今日盘中股价暴涨383.18%，创下历史新高，并因波动过大触发临时停牌。
消息面上，公司公布了其评估DMD（杜氏肌营养不良症）德拉米细胞疗法的3期HOPE-3试验的顶线结果。试验显示，与安慰剂相比，Deramiocel疗法将患者上肢功能下降速度减缓了54%，心脏功能恶化速度减缓了91%，均达到统计学意义。该结果标志着疗法在关键临床终点上的成功。
公司表示，已与美国FDA达成一致，将以此试验数据支持Deramiocel的批准申请。此前FDA曾因疗效数据不足拒绝批准该疗法，此次结果有望重新推动审批进程。分析师认为，数据明确显示了疗效信号，预计将获得批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.